This document provides an agenda and background information for a medical devices panel meeting on the LINX Reflux Management System. The agenda includes presentations on the pathophysiology of GERD, an overview of the LINX device and its pre-clinical testing, results from the LINX feasibility and pivotal clinical trials, post-market studies, and closing comments. The document also provides context on the company that developed LINX, the regulatory timeline for LINX, clinical experience with LINX to date, and an overview of the intended focus of today's meeting.
This study aimed to evaluate the feasibility, safety, and tissue response of a resorbable poly-l-lactide Eustachian tube stent in two animal models. Stents were implanted in chinchilla and rabbit ears. Results showed stents were easily implanted and well tolerated, with only transient infections in some subjects. Stents induced minimal inflammation. Differential resorption was seen, with minimal resorption at 6 months in chinchillas. Further testing is needed to determine appropriate sterilization and clarify resorption, with the goal of improving biocompatibility and reducing biofilm formation.
Incisionless procedures and stomach pacemaker for obesityforegutsurgeon
The document discusses emerging endoscopic and neuromodulation procedures for obesity treatment as alternatives to conventional bariatric surgery. It describes several primary endoscopic bariatric procedures like ValenTx sleeve and TOGA that provide 15-40% excess weight loss. It also reviews implantable gastric stimulators like Transcend IGS, MetaCure, and VBLOC therapy that use electrical pulses to induce satiety and reduce appetite through vagal modulation, resulting in 10-35% excess weight loss. These new procedures aim to offer minimally invasive options for less severe obesity with fewer lifestyle changes compared to standard bariatric surgery.
This document provides descriptions of physical characteristics for various fish species found in Oklahoma waters. It describes distinguishing features such as body shape, fin shape, mouth position, coloration, spots and bars for 29 different species, including sunfish, bass, catfish and others. Key identifying characteristics are emphasized to tell species apart, such as snout length and spotting patterns in different gar species, and fin ray counts and spotting patterns for crappie and redhorse suckers.
Mr. P, a 67-year-old male, presented to the emergency department with central chest pain radiating to his lower jaw and left arm. An ECG showed ST segment elevation in leads II, III, and AVF as well as ST segment depression in leads AVL and V3, indicating an acute inferoposterior myocardial infarction involving the right side. He received intravenous streptokinase therapy, aspirin, and glyceryl trinitrate, was admitted to the cardiac care unit, and had a Killips class II presentation.
Diagnostico y tratamiento de Patologias que afectan al ano-recto.
Enfermedad hemorroidal, Fisura anal, Fistula perianal y Rectovaginal, Absceso perianal, Quiste pilonidal
This document summarizes a presentation on fecal incontinence and its treatments. It begins with an overview of fecal incontinence, including its prevalence, impact on quality of life, and typical treatment pathway. It then discusses conservative treatments like diet and medication. Surgical options are explored in more detail, including sphincter repair and augmentation techniques like bulking agents and radiofrequency. Outcomes data is presented for these approaches. The document also summarizes sacral nerve stimulation, including its mechanism of action and results from multiple studies showing its effectiveness in reducing incontinence episodes and improving quality of life. Risks associated with sacral nerve stimulation like infection and device issues are also reviewed.
Fecal incontinence is more prevalent in patients with scleroderma compared to the general population. It can be caused by structural abnormalities of the internal and external anal sphincters as well as neurological and stool abnormalities. Diagnostic tests like anorectal manometry and endoanal ultrasound can identify abnormalities. Treatment options include lifestyle modifications, biofeedback, bulking agents, sacral nerve stimulation, and surgery. However, no treatment has been proven highly effective for fecal incontinence in scleroderma patients.
This study aimed to evaluate the feasibility, safety, and tissue response of a resorbable poly-l-lactide Eustachian tube stent in two animal models. Stents were implanted in chinchilla and rabbit ears. Results showed stents were easily implanted and well tolerated, with only transient infections in some subjects. Stents induced minimal inflammation. Differential resorption was seen, with minimal resorption at 6 months in chinchillas. Further testing is needed to determine appropriate sterilization and clarify resorption, with the goal of improving biocompatibility and reducing biofilm formation.
Incisionless procedures and stomach pacemaker for obesityforegutsurgeon
The document discusses emerging endoscopic and neuromodulation procedures for obesity treatment as alternatives to conventional bariatric surgery. It describes several primary endoscopic bariatric procedures like ValenTx sleeve and TOGA that provide 15-40% excess weight loss. It also reviews implantable gastric stimulators like Transcend IGS, MetaCure, and VBLOC therapy that use electrical pulses to induce satiety and reduce appetite through vagal modulation, resulting in 10-35% excess weight loss. These new procedures aim to offer minimally invasive options for less severe obesity with fewer lifestyle changes compared to standard bariatric surgery.
This document provides descriptions of physical characteristics for various fish species found in Oklahoma waters. It describes distinguishing features such as body shape, fin shape, mouth position, coloration, spots and bars for 29 different species, including sunfish, bass, catfish and others. Key identifying characteristics are emphasized to tell species apart, such as snout length and spotting patterns in different gar species, and fin ray counts and spotting patterns for crappie and redhorse suckers.
Mr. P, a 67-year-old male, presented to the emergency department with central chest pain radiating to his lower jaw and left arm. An ECG showed ST segment elevation in leads II, III, and AVF as well as ST segment depression in leads AVL and V3, indicating an acute inferoposterior myocardial infarction involving the right side. He received intravenous streptokinase therapy, aspirin, and glyceryl trinitrate, was admitted to the cardiac care unit, and had a Killips class II presentation.
Diagnostico y tratamiento de Patologias que afectan al ano-recto.
Enfermedad hemorroidal, Fisura anal, Fistula perianal y Rectovaginal, Absceso perianal, Quiste pilonidal
This document summarizes a presentation on fecal incontinence and its treatments. It begins with an overview of fecal incontinence, including its prevalence, impact on quality of life, and typical treatment pathway. It then discusses conservative treatments like diet and medication. Surgical options are explored in more detail, including sphincter repair and augmentation techniques like bulking agents and radiofrequency. Outcomes data is presented for these approaches. The document also summarizes sacral nerve stimulation, including its mechanism of action and results from multiple studies showing its effectiveness in reducing incontinence episodes and improving quality of life. Risks associated with sacral nerve stimulation like infection and device issues are also reviewed.
Fecal incontinence is more prevalent in patients with scleroderma compared to the general population. It can be caused by structural abnormalities of the internal and external anal sphincters as well as neurological and stool abnormalities. Diagnostic tests like anorectal manometry and endoanal ultrasound can identify abnormalities. Treatment options include lifestyle modifications, biofeedback, bulking agents, sacral nerve stimulation, and surgery. However, no treatment has been proven highly effective for fecal incontinence in scleroderma patients.
Incorporating Peripherally Inserted Central Catheters (PICC) into hospital cl...HTAi Bilbao 2012
This document summarizes the evidence-based incorporation of peripherally inserted central catheters (PICC) for cancer patients at Araba University Hospital. A literature review and training program was conducted before developing a protocol for PICC insertion, maintenance, and patient education. Over 200 PICCs were successfully inserted with few complications. PICCs provided a safe, effective long-term venous access alternative to implanted ports or central venous catheters at a lower cost. The process demonstrated how new technologies can be incorporated into clinical practice using an evidence-based approach.
Despite advances in treatment of bowel cancer, it remains the second most common cause of cancer death in the Western world. Use of drugs or nutritional supplements (chemoprevention) is an attractive strategy for prevention of bowel cancer in combination with other modalities such as population screening and endoscopic surveillance, particularly if the chemoprevention agent is safe, well tolerated and cost effective. This webinar describes existing evidence that omega-3 fatty acids have activity against bowel cancer. Recent completed and ongoing clinical trials of EPA for primary prevention of bowel cancer and prevention of metastatic disease are described. Current thinking about how omega-3 fatty acids might work against bowel cancer are also explained.
6. Future viable steps to reduce antibiotic usage in.pptx2damcreative
This document discusses potential future steps to reduce antibiotic usage in commercial beef production. It outlines why antibiotic reduction is needed due to increasing antibiotic resistance. It then discusses various strategies that can be used to reduce antibiotic usage, including procuring healthier cattle, pre-vaccinating and backgrounding cattle before feedlot entry, improving stockmanship and acclimation practices, more precise disease diagnosis, and alternatives to in-feed antibiotics like direct fed microbials. The overall goal is to reduce sickness in feedlots and thereby reduce the need for antibiotic treatments.
Dr. Rich Carnevale - The Future of AntimicrobialsJohn Blue
The Future of Antimicrobials - Dr. Rich Carnevale, AHI, VP Regulatory, Scientific & International Affairs , from the 2012 NIAA One Health Approach to Antimicrobial Resistance and Use Symposium, October 26-27, 2012, Columbus, OH, USA.
More presentations at:
http://www.trufflemedia.com/agmedia/conference/2012-one-health-to-approach-antimicrobial-resistance-and-use
YM BioSciences 2012 Annual Meeting of ShareholdersYMBioSciences
The document is a presentation from YM BioSciences' 2012 Annual General Meeting. It summarizes the company's strategic priorities for the fiscal year, including ensuring optimization of their lead drug CYT387 for myelofibrosis. It provides clinical data from trials of CYT387 showing benefits in reducing anemia, splenomegaly, and constitutional symptoms in myelofibrosis patients. The presentation outlines YM's development pathway for CYT387, including next steps of presenting additional data at ASH 2012 and exploring partnerships or advancing CYT387 into Phase III trials.
Professor Peter Littlejohns: NICE current practice and future directionNuffield Trust
NICE currently provides national guidance on health promotion and disease prevention and treatment. It issues guidance in public health, health technologies, and clinical practice based on comprehensive evidence reviews and expert input. NICE will take on responsibility for social care guidance in 2012. Quality standards are being developed to define high quality care and will include 150 topics over 5 years. NICE's guidance and quality standards will play a key role in the new NHS Outcomes Framework and in determining provider payment mechanisms. This expanded role may impact national and local priority setting.
This document discusses dissolution testing, which is used to evaluate how quickly an active pharmaceutical ingredient is released from its solid dosage form after administration. Key points include:
- Dissolution is the process by which a solid enters solution and is controlled by the affinity between the solid and solvent.
- Dissolution testing seeks to relate in vitro dissolution to in vivo drug absorption and bioavailability.
- The Biopharmaceutics Classification System categorizes drugs based on their solubility and permeability properties to determine the rate-limiting step of absorption.
- Procedures for dissolution testing must account for factors like pH, surfactants, and apparatus to mimic conditions in the gastrointestinal tract.
- Diss
Environmental analysis can be extremely challenging due to the low detection levels for toxic contaminants specified by legislation, particularly in drinking water, and the complexity of matrices encountered. Consequently highly selective and sensitive detection methods are required. This presentation provides an introduction to tandem quadrupole mass spectrometry and describes the use of high sensitivity tandem quadrupole mass spectrometry for the analysis of various environmental contaminants including pesticides, endocrine disruptors and polyfluorinated compounds such as PFOS.
Dr. Nick Gabler - The impact of PRRSV on feed efficiency, digestibility and t...John Blue
The impact of PRRSV on feed efficiency, digestibility and tissue accretion in grow-finisher pigs - Dr. Nick Gabler, Department of Animal Science, Iowa State University, from the 2013 Allen D. Leman Swine Conference, September 14-17, 2013, St. Paul, Minnesota, USA.
More presentations at http://www.swinecast.com/2013-leman-swine-conference-material
Presentation delivered during a Hospital Efficiency Seminar hosted by Institute for Healthcare Optimization on July 25, 2013. Reviews Mayo Clinic experience and outcomes with using variability theory to re-design the management of the operating rooms at Mayo Clinic Florida.
Early Results With Linx and Lessons for Implementation in PracticeC Daniel Smith
This document discusses the early clinical outcomes of introducing a mechanical sphincter augmentation device called LINX for the treatment of GERD. It summarizes the experience from the first 66 patients treated at a single institution. The procedure had a high rate of successful implantation with no complications. Early outcomes showed 83% of patients were off PPIs with high satisfaction rates. Recovery from dysphagia and esophageal clearance issues took longer than typical anti-reflux surgery due to the constant pressure from the device. Careful patient selection and education as well as differentiated post-op management from fundoplication patients were emphasized for successful adoption of this new therapy into clinical practice.
SureSELECT - Operating Room and Hospital Resource Utilization Schedule Optimi...C Daniel Smith
Optimizing the flow of a surgical patient through the operating room helps ensure the greatest value in the care of that patient. To achieve this optimized flow, the resources needed to provide care through the entire episode of care need to be coordinated.
Coordinating these varied and often disintegrated resources is often nearly impossible without the dedicated time of multiple FTEs to manage the schedules and resources of the different segments of care.
The starting point for the flow of a surgical patient is their placement on the operating room schedule. SureSELECT surveys and assesses all the resources needed for a specific patient’s care and provides the optimized placement on the operating room schedule to achieve optimal flow. Proprietary algorithms assure that all resources are available “just-in-time” throughout the patient’s care.
Re-engineering the Operating Room Using Variability Methodology to Improve He...C Daniel Smith
Hospitals across the country are aggressively pursuing cost-cutting strategies, and the high-value, high-cost environment of the operating room is a prime target for cost reduction.
Applying variability methodology swings the pendulum for access to the hospital’s operating rooms from “whatever and whenever” the surgeon wants, to what is best for the hospital. Put more directly, in this model, the surgeon is asked to compromise to meet the hospital’s financial needs. The resultant tension between a surgeon and hospital administration can become intense and was certainly present during the redesign and implementation detailed in this case study.
Software and information technology tools to help schedule surgical cases within the redesign goals, and reporting tools within a quantitative dashboard are essential to facilitate adoption of this program. Transparency regarding leadership decisions and frequent feedback to all providers about performance improvements should be emphasized. Change management and analytics support should be identified either internally or pursued externally before starting such a program.
Improving Surgical Safety and Patient OutcomesC Daniel Smith
Keynote talk delivered at New Jersey Hospital Association Seminary on Improving Surgical Safety & Patient Outcomes held on September 25, 2013 at their Conference Center in Princeton New Jersey. Over physicians, administrators, nurses and perioperative services providers in attendance.
Surgery Grand rounds Presentation at Rush University Medical Center on March 20, 2013. Presentation highlights clinical use of Prone Thoracoscopy, Fluorescence Angiography, Transcervical Videoscopic Esophageal Dissection (TVED) and Linx.
Slides from recent presentation at Mayo Clinic course on advances in gastroenterology. These are the slides that are a part of the video presentation of this same talk.
Innovations in Minimally Invasive Surgery 2011C Daniel Smith
The document summarizes a presentation given by Dr. C. Daniel Smith at the Florida Gastroenterologic Society Annual Meeting in September 2010. The presentation covered recent innovations in minimally invasive GI surgery, including natural orifice translumenal endoscopic surgery (NOTES), single incision laparoscopic surgery (SILS), minimally invasive esophagectomy, and innovations in antireflux surgery devices. The presentation provided details on the techniques, outcomes, adoption rates, and impacts of these new minimally invasive surgical innovations.
The document discusses establishing the LINX Reflux Management System as a surgical offering for treating GERD. It provides context on the current treatment landscape including the role and limitations of Nissen fundoplication and PPI therapy. Key points made include defining the typical LINX patient as one with moderate GERD symptoms remaining on PPIs, presenting efficacy data from the pivotal trial showing high rates of PPI independence and symptom improvement, and emphasizing the importance of patient selection and standardized surgical technique for achieving good outcomes.
This document summarizes a presentation on the surgical treatment of achalasia given at the 2012 SAGES Annual Meeting. It provides background on achalasia, including epidemiology and etiology. It discusses current treatment options and their outcomes, with surgical myotomy shown to have the highest long-term success rate of 92%. The presentation explores ongoing controversies in surgical treatment and also discusses emerging endoscopic options like per oral endoscopic myotomy. It emphasizes that patient selection and surgical technique are two key predictors of outcome for treating achalasia.
More Related Content
Similar to FDA Advisory Panel Linx Presentation 011112
Incorporating Peripherally Inserted Central Catheters (PICC) into hospital cl...HTAi Bilbao 2012
This document summarizes the evidence-based incorporation of peripherally inserted central catheters (PICC) for cancer patients at Araba University Hospital. A literature review and training program was conducted before developing a protocol for PICC insertion, maintenance, and patient education. Over 200 PICCs were successfully inserted with few complications. PICCs provided a safe, effective long-term venous access alternative to implanted ports or central venous catheters at a lower cost. The process demonstrated how new technologies can be incorporated into clinical practice using an evidence-based approach.
Despite advances in treatment of bowel cancer, it remains the second most common cause of cancer death in the Western world. Use of drugs or nutritional supplements (chemoprevention) is an attractive strategy for prevention of bowel cancer in combination with other modalities such as population screening and endoscopic surveillance, particularly if the chemoprevention agent is safe, well tolerated and cost effective. This webinar describes existing evidence that omega-3 fatty acids have activity against bowel cancer. Recent completed and ongoing clinical trials of EPA for primary prevention of bowel cancer and prevention of metastatic disease are described. Current thinking about how omega-3 fatty acids might work against bowel cancer are also explained.
6. Future viable steps to reduce antibiotic usage in.pptx2damcreative
This document discusses potential future steps to reduce antibiotic usage in commercial beef production. It outlines why antibiotic reduction is needed due to increasing antibiotic resistance. It then discusses various strategies that can be used to reduce antibiotic usage, including procuring healthier cattle, pre-vaccinating and backgrounding cattle before feedlot entry, improving stockmanship and acclimation practices, more precise disease diagnosis, and alternatives to in-feed antibiotics like direct fed microbials. The overall goal is to reduce sickness in feedlots and thereby reduce the need for antibiotic treatments.
Dr. Rich Carnevale - The Future of AntimicrobialsJohn Blue
The Future of Antimicrobials - Dr. Rich Carnevale, AHI, VP Regulatory, Scientific & International Affairs , from the 2012 NIAA One Health Approach to Antimicrobial Resistance and Use Symposium, October 26-27, 2012, Columbus, OH, USA.
More presentations at:
http://www.trufflemedia.com/agmedia/conference/2012-one-health-to-approach-antimicrobial-resistance-and-use
YM BioSciences 2012 Annual Meeting of ShareholdersYMBioSciences
The document is a presentation from YM BioSciences' 2012 Annual General Meeting. It summarizes the company's strategic priorities for the fiscal year, including ensuring optimization of their lead drug CYT387 for myelofibrosis. It provides clinical data from trials of CYT387 showing benefits in reducing anemia, splenomegaly, and constitutional symptoms in myelofibrosis patients. The presentation outlines YM's development pathway for CYT387, including next steps of presenting additional data at ASH 2012 and exploring partnerships or advancing CYT387 into Phase III trials.
Professor Peter Littlejohns: NICE current practice and future directionNuffield Trust
NICE currently provides national guidance on health promotion and disease prevention and treatment. It issues guidance in public health, health technologies, and clinical practice based on comprehensive evidence reviews and expert input. NICE will take on responsibility for social care guidance in 2012. Quality standards are being developed to define high quality care and will include 150 topics over 5 years. NICE's guidance and quality standards will play a key role in the new NHS Outcomes Framework and in determining provider payment mechanisms. This expanded role may impact national and local priority setting.
This document discusses dissolution testing, which is used to evaluate how quickly an active pharmaceutical ingredient is released from its solid dosage form after administration. Key points include:
- Dissolution is the process by which a solid enters solution and is controlled by the affinity between the solid and solvent.
- Dissolution testing seeks to relate in vitro dissolution to in vivo drug absorption and bioavailability.
- The Biopharmaceutics Classification System categorizes drugs based on their solubility and permeability properties to determine the rate-limiting step of absorption.
- Procedures for dissolution testing must account for factors like pH, surfactants, and apparatus to mimic conditions in the gastrointestinal tract.
- Diss
Environmental analysis can be extremely challenging due to the low detection levels for toxic contaminants specified by legislation, particularly in drinking water, and the complexity of matrices encountered. Consequently highly selective and sensitive detection methods are required. This presentation provides an introduction to tandem quadrupole mass spectrometry and describes the use of high sensitivity tandem quadrupole mass spectrometry for the analysis of various environmental contaminants including pesticides, endocrine disruptors and polyfluorinated compounds such as PFOS.
Dr. Nick Gabler - The impact of PRRSV on feed efficiency, digestibility and t...John Blue
The impact of PRRSV on feed efficiency, digestibility and tissue accretion in grow-finisher pigs - Dr. Nick Gabler, Department of Animal Science, Iowa State University, from the 2013 Allen D. Leman Swine Conference, September 14-17, 2013, St. Paul, Minnesota, USA.
More presentations at http://www.swinecast.com/2013-leman-swine-conference-material
Similar to FDA Advisory Panel Linx Presentation 011112 (10)
Presentation delivered during a Hospital Efficiency Seminar hosted by Institute for Healthcare Optimization on July 25, 2013. Reviews Mayo Clinic experience and outcomes with using variability theory to re-design the management of the operating rooms at Mayo Clinic Florida.
Early Results With Linx and Lessons for Implementation in PracticeC Daniel Smith
This document discusses the early clinical outcomes of introducing a mechanical sphincter augmentation device called LINX for the treatment of GERD. It summarizes the experience from the first 66 patients treated at a single institution. The procedure had a high rate of successful implantation with no complications. Early outcomes showed 83% of patients were off PPIs with high satisfaction rates. Recovery from dysphagia and esophageal clearance issues took longer than typical anti-reflux surgery due to the constant pressure from the device. Careful patient selection and education as well as differentiated post-op management from fundoplication patients were emphasized for successful adoption of this new therapy into clinical practice.
SureSELECT - Operating Room and Hospital Resource Utilization Schedule Optimi...C Daniel Smith
Optimizing the flow of a surgical patient through the operating room helps ensure the greatest value in the care of that patient. To achieve this optimized flow, the resources needed to provide care through the entire episode of care need to be coordinated.
Coordinating these varied and often disintegrated resources is often nearly impossible without the dedicated time of multiple FTEs to manage the schedules and resources of the different segments of care.
The starting point for the flow of a surgical patient is their placement on the operating room schedule. SureSELECT surveys and assesses all the resources needed for a specific patient’s care and provides the optimized placement on the operating room schedule to achieve optimal flow. Proprietary algorithms assure that all resources are available “just-in-time” throughout the patient’s care.
Re-engineering the Operating Room Using Variability Methodology to Improve He...C Daniel Smith
Hospitals across the country are aggressively pursuing cost-cutting strategies, and the high-value, high-cost environment of the operating room is a prime target for cost reduction.
Applying variability methodology swings the pendulum for access to the hospital’s operating rooms from “whatever and whenever” the surgeon wants, to what is best for the hospital. Put more directly, in this model, the surgeon is asked to compromise to meet the hospital’s financial needs. The resultant tension between a surgeon and hospital administration can become intense and was certainly present during the redesign and implementation detailed in this case study.
Software and information technology tools to help schedule surgical cases within the redesign goals, and reporting tools within a quantitative dashboard are essential to facilitate adoption of this program. Transparency regarding leadership decisions and frequent feedback to all providers about performance improvements should be emphasized. Change management and analytics support should be identified either internally or pursued externally before starting such a program.
Improving Surgical Safety and Patient OutcomesC Daniel Smith
Keynote talk delivered at New Jersey Hospital Association Seminary on Improving Surgical Safety & Patient Outcomes held on September 25, 2013 at their Conference Center in Princeton New Jersey. Over physicians, administrators, nurses and perioperative services providers in attendance.
Surgery Grand rounds Presentation at Rush University Medical Center on March 20, 2013. Presentation highlights clinical use of Prone Thoracoscopy, Fluorescence Angiography, Transcervical Videoscopic Esophageal Dissection (TVED) and Linx.
Slides from recent presentation at Mayo Clinic course on advances in gastroenterology. These are the slides that are a part of the video presentation of this same talk.
Innovations in Minimally Invasive Surgery 2011C Daniel Smith
The document summarizes a presentation given by Dr. C. Daniel Smith at the Florida Gastroenterologic Society Annual Meeting in September 2010. The presentation covered recent innovations in minimally invasive GI surgery, including natural orifice translumenal endoscopic surgery (NOTES), single incision laparoscopic surgery (SILS), minimally invasive esophagectomy, and innovations in antireflux surgery devices. The presentation provided details on the techniques, outcomes, adoption rates, and impacts of these new minimally invasive surgical innovations.
The document discusses establishing the LINX Reflux Management System as a surgical offering for treating GERD. It provides context on the current treatment landscape including the role and limitations of Nissen fundoplication and PPI therapy. Key points made include defining the typical LINX patient as one with moderate GERD symptoms remaining on PPIs, presenting efficacy data from the pivotal trial showing high rates of PPI independence and symptom improvement, and emphasizing the importance of patient selection and standardized surgical technique for achieving good outcomes.
This document summarizes a presentation on the surgical treatment of achalasia given at the 2012 SAGES Annual Meeting. It provides background on achalasia, including epidemiology and etiology. It discusses current treatment options and their outcomes, with surgical myotomy shown to have the highest long-term success rate of 92%. The presentation explores ongoing controversies in surgical treatment and also discusses emerging endoscopic options like per oral endoscopic myotomy. It emphasizes that patient selection and surgical technique are two key predictors of outcome for treating achalasia.
The Linx Reflux Management System is a bracelet of magnetic beads that is surgically placed around the esophagus. The magnetic force holds the bracelet closed to prevent acid reflux but opens in response to swallowed food. It has been tested in humans for over 4 years and approved by the FDA in 2012. Candidates must have a confirmed GERD diagnosis but no Barrett's esophagus or large hiatal hernia. The procedure is performed laparoscopically and patients can resume a normal diet immediately after. The device is available at centers with GERD expertise.
A study of 97 patients who underwent esophagectomy between 2007-2010 found that:
1) Minimally invasive esophagectomy (MIE) was associated with fewer pulmonary and cardiac complications compared to open approaches, but the differences were not statistically significant.
2) Rates of anastomotic leaks, renal complications, wound infections, and in-hospital mortality were similar between MIE and open approaches.
3) Trans-thoracic approaches to esophagectomy, whether open or minimally invasive, were associated with higher morbidity than cervical or transhiatal approaches.
Cell Therapy Expansion and Challenges in Autoimmune DiseaseHealth Advances
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
Adhd Medication Shortage Uk - trinexpharmacy.comreignlana06
The UK is currently facing a Adhd Medication Shortage Uk, which has left many patients and their families grappling with uncertainty and frustration. ADHD, or Attention Deficit Hyperactivity Disorder, is a chronic condition that requires consistent medication to manage effectively. This shortage has highlighted the critical role these medications play in the daily lives of those affected by ADHD. Contact : +1 (747) 209 – 3649 E-mail : sales@trinexpharmacy.com
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central19various
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Hiranandani Hospital in Powai, Mumbai, is a premier healthcare institution that has been serving the community with exceptional medical care since its establishment. As a part of the renowned Hiranandani Group, the hospital is committed to delivering world-class healthcare services across a wide range of specialties, including kidney transplantation. With its state-of-the-art facilities, advanced medical technology, and a team of highly skilled healthcare professionals, Hiranandani Hospital has earned a reputation as a trusted name in the healthcare industry. The hospital's patient-centric approach, coupled with its focus on innovation and excellence, ensures that patients receive the highest standard of care in a compassionate and supportive environment.
Rasamanikya is a excellent preparation in the field of Rasashastra, it is used in various Kushtha Roga, Shwasa, Vicharchika, Bhagandara, Vatarakta, and Phiranga Roga. In this article Preparation& Comparative analytical profile for both Formulationon i.e Rasamanikya prepared by Kushmanda swarasa & Churnodhaka Shodita Haratala. The study aims to provide insights into the comparative efficacy and analytical aspects of these formulations for enhanced therapeutic outcomes.
- Video recording of this lecture in English language: https://youtu.be/Pt1nA32sdHQ
- Video recording of this lecture in Arabic language: https://youtu.be/uFdc9F0rlP0
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
share - Lions, tigers, AI and health misinformation, oh my!.pptxTina Purnat
• Pitfalls and pivots needed to use AI effectively in public health
• Evidence-based strategies to address health misinformation effectively
• Building trust with communities online and offline
• Equipping health professionals to address questions, concerns and health misinformation
• Assessing risk and mitigating harm from adverse health narratives in communities, health workforce and health system
These lecture slides, by Dr Sidra Arshad, offer a simplified look into the mechanisms involved in the regulation of respiration:
Learning objectives:
1. Describe the organisation of respiratory center
2. Describe the nervous control of inspiration and respiratory rhythm
3. Describe the functions of the dorsal and respiratory groups of neurons
4. Describe the influences of the Pneumotaxic and Apneustic centers
5. Explain the role of Hering-Breur inflation reflex in regulation of inspiration
6. Explain the role of central chemoreceptors in regulation of respiration
7. Explain the role of peripheral chemoreceptors in regulation of respiration
8. Explain the regulation of respiration during exercise
9. Integrate the respiratory regulatory mechanisms
10. Describe the Cheyne-Stokes breathing
Study Resources:
1. Chapter 42, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 36, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 13, Human Physiology by Lauralee Sherwood, 9th edition
1. LINX® Reflux Management System
Gastroenterology and Urology
Medical Devices Panel Meeting,
January 11, 2012
Gaithersburg, MD
2. AGENDA
Todd Berg
Introduction CEO
Torax Medical
Tom DeMeester, MD
Pathophysiology of GERD Professor of Surgery, Chair Emeritus
Department of Surgery -- USC
Device Overview and Todd Berg
CEO
Pre-Clinical Activities Torax Medical
LINX Feasibility and Pivotal Daniel Smith, MD
Chair Department of Surgery – Mayo
IDE Clinical Trials Jacksonville
Todd Berg
Post Market Studies and CEO
Torax Medical
Closing Comments
3. Torax Medical, Inc.
November 2002
Founded:
Minneapolis – St. Paul, MN
To develop a device to improve the barrier
Objective:
function of the esophageal sphincter
Company
Engineering and Physician collaboration
Approach:
4. Regulatory Timeline – LINX Reflux
Management System
2005 2006 2007 2008 2009 2010 2011 2012
Design
freeze
GLP Animal Studies
and Final Pre-Clinical
Testing
Enrollment
Feasibility IDE
Enrollment of
Pivotal IDE
PMA Filing
PMA
Amendment
2-year
follow-up
FDA Panel
Meeting
5. Clinical Experience Overview
LINX Experience
Feasibility and Pivotal IDE Clinical Trials
Commercially available in Europe
Published Papers
Gastrointestinal Endoscopy – Feb 2008
Journal of Gastrointestinal Surgery – Dec 2008
Annals of Surgery – Nov 2010
Investigator Engagement
All investigators remain actively engaged with a continued
collaboration of data and experiences
6. Today’s Focus
Device LINX Reflux Management System
Chronic GERD symptoms despite long-term acid
Patient Profile
suppression therapy
Therapeutic Reduction in esophageal acid exposure, control
Benefit of heartburn, and elimination of PPI use
7. Evidence of Reduced Acid Exposure
90% (86/96) Achieved Reduced Esophageal Acid Exposure
100
75
Reduction in Total Time pH<4 (%)
50
25
0
-25
-50
-75
-100
8. Evidence of Reduced Acid Exposure
90% (86/96) Achieved Reduced Esophageal Acid Exposure
100
75
Reduction in Total Time pH<4 (%)
50
25
0
-25
-50
-75
-100
9. GERD HRQL Score Reduction at 1 Year
99% (94/95) Achieved Reduction in HRQL Scores
100
75
Percent Reduction in GERD HRQL Score
50
25
0
-25
-50
-75
-100
10. GERD HRQL Score Reduction at 2 Years
99% (89/90) Achieved Reduction in HRQL Scores
100
75
Percent Reduction in GERD HRQL Score
50
25
0
-25
-50
-75
-100
11. PPI Free Days
As of Last Follow-Up
900
800
700
600
PPI Free Days
500
400
300
200
100
0
13. AGENDA
Todd Berg
Introduction CEO
Torax Medical
Tom DeMeester, MD
Pathophysiology of GERD Professor of Surgery, Chair Emeritus
Department of Surgery -- USC
Device Overview and Todd Berg
CEO
Pre-Clinical Activities Torax Medical
LINX Feasibility and Pivotal Daniel Smith, MD
Chair Department of Surgery – Mayo
IDE Clinical Trials Jacksonville
Todd Berg
Post Market Studies and CEO
Torax Medical
Closing Comments
14. Pathophysiology of GERD
Tom DeMeester, MD
Professor of Surgery, Chair Emeritus,
Department of Surgery, USC
15. GERD is a chronic progressive
disease that affects 10-20% of
adults in the western world.
Dent J. Gut 2005;54:710-717
Clinical Spectrum
Treatable Sym. Treatable Persistent
(Non Erosive Symptoms & Symptoms or Barrett’s
Disease) Esophagitis Esophagitis
Lord et al. J Gastrointest Surg 2009;13:602-610
16. Fundamental Abnormality of GERD
Primary
Loss of an
effective sphincter
Secondary
Composition of the
refluxed gastric
juice
19. Number and Type of Reflux Episodes:
On and Off PPI
Total / 24 h
Acid / 24 h
Weakly Acidic / 24 h
P = 0.341
Weakly Alkaline / 24 h
P < 0.001
P < 0.001
120
Number of reflux episodes
P = 0.958
100
80
60
40
20
0
Off PPI On PPI
Hemmink GJM et al., Am J Gastroenterol 2008;103:2446-53
20. Patient’s Anxiety: 2012
• Persistent symptoms despite PPI therapy
• Life long medication dependency
• Outcome, side effects and finality of a
Nissen fundoplication.
• What does this mean for me in the long
term?
22. Samelson’s Observation
Loose
Ligature
Distension
SL Samelson, HF Weiser, CT Bombeck, JR Siewert, FE Ludtke, AH Hoelscher, SF Abuabara, LM Nyhus,
Ann Surg,1983;197:254-259
23. Sphincter Augmentation with a Loose Ligature
No ligature Ligature in place
SL Samelson, HF Weiser, CT Bombeck, JR Siewert, FE Ludtke, AH Hoelscher, SF Abuabara,
LM Nyhus, Ann Surg,1983;197:254-259
24. The LINX Sphincter Augmentation Device
A loose ligature
of expanding
magnetic
beads
Distension
26. AGENDA
Todd Berg
Introduction CEO
Torax Medical
Tom DeMeester, MD
Pathophysiology of GERD Professor of Surgery, Chair Emeritus
Department of Surgery -- USC
Device Overview and Todd Berg
CEO
Pre-Clinical Activities Torax Medical
LINX Feasibility and Pivotal Daniel Smith, MD
Chair Department of Surgery – Mayo
IDE Clinical Trials Jacksonville
Todd Berg
Post Market Studies and CEO
Torax Medical
Closing Comments
28. The Esophageal Sphincter
Reflux occurs due to
Esophageal
Sphincter abnormal sphincter
opening
Development goal -
minimize abnormal
opening without
changing normal
sphincter functions
36. Pre-Clinical Objectives
The LINX Reflux Management System has
undergone extensive pre-clinical testing to assess
the following properties:
• Physiologically compatible forces
• Biocompatibility and bio-stability
• Long term durability
37. Physiologically Based Magnetic Forces
Yield pressure studies showed that gastric yield pressure
directly correlated with increasing magnet forces
Ganz, R, Gostout, C, Grudem, J, et al. Use of a magnetic sphincter for the treatment of GERD; a feasibility
study. GIE 2008;16: 287-294
38. Physiologic Design of LINX
• Very small volume; <2cc
• No chronic forces at rest
• Compatible with esophageal
movements
39. Stable Healing Response
Histologic examinations did not present any significant
safety concerns and were consistent with a typical foreign
body response
Esophagus LINX Fibrous
Lumen Bead Capsule
In-tact
Muscular
Layer
Mucosa
40. Pre-Clinical Conclusions
The LINX device remains compliant after healing
Mechanically durable
No signs of erosion or migration
Magnetic forces compatible with sphincter
functions
42. Pivotal Study Design Considerations
Randomized Control
Nissen
Enrollment and Standardization concerns
PPI
Insufficient for treatment group
Documented history of use
Standardizing drug regimens difficult
Placebo Considerations
Objective measures
Long-term follow-up
43. Pivotal Study Design Rationale
Single-arm, self-controlled trial is
appropriate:
Patient specific disease history
Apply multiple measures of effectiveness
Provide long-term follow-up
Include objective measures
44. Pivotal Trial Endpoints
EFFICACY >60% of subjects will achieve success1
Primary
Normalize or reduce by >50% the total %
Reduced Esophageal Acid Exposure time
Secondary
Reduce by >50% total GERD-HRQL score
Heartburn Reduction-GERD HRQL
Secondary
Reduce by >50% average daily PPI usage
Reduced PPI dependence
Estimate rate of related Serious Adverse
SAFETY OBJECTIVE
Events
1-Based on a lower bound 97.5% CI
45. LINX Indication
Proposed LINX Indication
The Torax LINX Reflux Management System is
indicated for those individuals diagnosed with
pathologic Gastroesophageal Reflux Disease (GERD)
as defined by abnormal pH testing and who continue to
have chronic GERD symptoms despite anti-reflux drug
therapy.
46. AGENDA
Todd Berg
Introduction CEO
Torax Medical
Tom DeMeester, MD
Pathophysiology of GERD Professor of Surgery, Chair Emeritus
Department of Surgery -- USC
Device Overview and Todd Berg
CEO
Pre-Clinical Activities Torax Medical
LINX Feasibility and Pivotal Daniel Smith, MD
Chair Department of Surgery – Mayo
IDE Clinical Trials Jacksonville
Todd Berg
Post Market Studies and CEO
Torax Medical
Closing Comments
47. LINX Safety and Effectiveness: Feasibility
and Pivotal Clinical Trials
C. Daniel Smith, MD
Professor & Chair
Department of Surgery
Mayo Clinic Florida
48. Feasibility and Pivotal IDE Trials
Feasibility Pivotal
Number of subjects 44 100
Number of centers 4 16
Prospective, patient own Prospective, patient own
Design
control group control group
• Pathologic reflux • Pathologic reflux
Patient enrollment • Chronic symptoms • Chronic symptoms
despite medical therapy despite medical therapy
First Implant Feb 2007 Jan 2009
Follow-up • Completed 2 and 3 year • Completed 2 year
• Planned to 5 year • Planned to 5 year
49. Measures of Effectiveness and Safety
Effectiveness
Reduction in esophageal acid exposure
Reduction in GERD-HRQL Score
Reduction in PPI Use
Safety
Serious Adverse Event Rate (SAE)
52. GERD-HRQL Score off PPI
Feasibility Pivotal
30
N=100
N=44
Mean GERD HRQL Score Off PPI
25
20
15
10
N=98 N=98 N=90
N=95
5
N=37 N=33 N=39 N=35
N=27
0
BL Off PPI 3 Month 6 Month 12 Month 24 Month 36 Month
53. Daily PPI Dependence
Feasiblity Pivotal
100
N=100
Percent of Patients Reporting Daily PPI Use
N=44
80
60
40
N=39 N=35
N=32
20
N=97
N=90
0
Baseline 12 month 24 month 36 month
54. Acceptable Safety Profile Established
144 subjects with implant 2 to 4 years
No intra-operative complications
No reports of device migration, erosion or
device failures
SAEs
4% Feasibility
6% Pivotal
56. Pivotal Trial Overview
Purpose To evaluate safety and effectiveness
Design Prospective, Multi-center, Single-arm
Control Subject as own control
257 screened
Subjects
100 implanted
12 months
Endpoint Analyses
Treatment Group (all implanted subjects)
Follow-up Discharge, 1wk, 3M, 6M, 12M – 60M (annually)
-Completed 24 months
12 months – 98%
-Subject Completion
24 months – 90%
57. Centers and Investigators
Abbott/ MNGI MN R. Ganz, D. Dunn
Albert Einstein Med Ctr PA P. Katz
American Med Ctr, Amsterdam, NL P. Fockens, W. Bemelman, A. Smout
Gundersen Lutheran WI S. Schlack-Haerer, S. Kothari
Knox Community OH P. Taiganides
Legacy Medical Center OR C. Dunst, L. Swanstrom
Mayo Jacksonville FL C.D. Smith, K. DeVault
Nashville Med Research TN R. Pruitt
Ohio State Univ OH S. Melvin
Phoebe Putney GA C. Smith
Univ of Pittsburgh PA J. Luketich
Univ of Rochester NY J. Peters
Univ of Washington WA C. Pellingrini, B. Oelschlager
Univ of CA – San Diego CA S. Horgan
Univ of Southern California CA J. Lipham
Washington University MO S. Edmundowicz, B. Matthews
58. Key Pivotal IDE Eligibility Criteria
Inclusion
Age 18-75 years
Typical GERD symptoms >6 months
Pathologic GERD – (esophageal pH<4 for >4.5% of time)
Daily PPI use
Symptomatic improvement on PPIs
Exclusion
Hiatal hernia (>3cm)
Esophagitis Grade C or D (LA classification)
Barrett’s esophagus
Esophageal motility disorder
59. Pivotal Trial Endpoints
EFFICACY >60% of subjects will achieve success1
Primary
Normalize or reduce by >50% the total %
Reduced Esophageal Acid Exposure time
Secondary
Reduce by >50% total GERD-HRQL score
Heartburn Reduction-GERD HRQL
Secondary
Reduce by >50% average daily PPI usage
Reduced PPI dependence
Estimate rate of related Serious Adverse
SAFETY OBJECTIVE
Events
1-Based on a lower bound 97.5% CI
60. Additional Pre-Specified Assessments
Efficacy Side Effects Safety
pH testing Ability to belch Dysphagia
GERD-HRQL Ability to vomit Pain
PPI use Diet Tolerance Motility
Regurgitation – frequency Gas bloat – frequency & Endoscopy
& severity severity
Esophagitis Barium swallow
Patient Satisfaction X-ray
Heartburn – frequency and Weight loss
severity
Extra-esophageal symptoms
All assessments were actively surveyed through study period.
62. Baseline Characteristics
Parameter Measurement Results (N = 100)
Age (years) Mean ±SD 50+12.4
BMI Mean ±SD 28±3.4
Gender % (n/N) Male 52%
Female 48%
Total % pH Time <4 Mean ±SD 12±4.7
Esophagitis (%) Grade A or B 40%
GERD-HRQL Total Mean ±SD
Score On PPI 12.0+6.8
Off PPI 26.6+6.6
63. GERD History - Baseline
RESULTS
(N = 100)
GERD
Mean 13 years
Duration of PPI Use
Mean 6 years
Heartburn – Moderate or Severe
Primary reason for visit and/or interfering with 89%
daily activities
Regurgitation – Moderate or Severe
With position change and/or constant presence 57%
of aspirations
64. Uncomplicated Surgical Procedure
Measurement Result
Surgical Procedure Time Mean +SD 39+22.8 minutes
(Last port in to first port removed)
Procedure Failure 0%
Operative Complication Rate 0%
Discharge SAE Rate 0%
Length of Stay
Same day discharge 50%
Next day discharge 50%
Note: No roll-in or training implants. All implants included in analysis.
66. Summary of Efficacy Endpoints
Percent Successful (95% Binomial Exact Confidence Limits)
Primary: pH
Normalization or ≥ 64% (:54, 73%)
50% reduction
Secondary: GERD
≥ 50% reduction in 92% (85, 97%)
GERD-HRQL
Secondary: PPI
≥ 50% reduction in 93% (86, 97%)
daily PPI use
0 10 20 30 40 50 60 70 80 90 100
67. Patients Not Achieving the pH Endpoint
Clinical Success Achieved and Maintained
Measurement Baseline 12 months 24 months
Mean Total GERD-HRQL 28.4 5.9 5.5
Score Off PPI
Daily PPI Use 100% 21% 17%
Regurgitation – Severe or
72% 6% 4%
Moderate
Esophagitis 44% 21% 17%
68. Pivotal Mean DeMeester Score
Components
BASE- 12
PARAMETER* N N P VALUE
LINE Month
Total time pH<4 (%) 100 11.6 96 5.1 <.0001
Total upright time pH<4 (%) 100 14.0 96 6.5 <.0001
Total supine time pH<4 (%) 98 7.8 95 2.9 <.0001
Total number of reflux episodes 100 175 96 82.8 <.0001
Number of reflux episodes >5min 99 12.4 96 6.1 <.0001
Longest reflux episode (min) 99 37.4 96 19.7 <.0001
DeMeester Score 97 41.0 95 18.7 <.0001
*All pH testing completed with Bravo capsule endoscopically placed
71. GERD-HRQL Questionnaire(1)
• Validated questionnaire, specific to GERD
• 10 Questions Scored
• 6 heartburn related
• 2 swallowing related
• 1 gassy/bloating
• 1 medication
• Scoring Scale 0 – 5
• 0 = No symptoms
• 1 = Symptoms noticeable but not bothersome
• 2 = Symptoms noticeable and bothersome
• 3 = Symptoms bothersome every day
• 4 = Symptoms affect daily activities
• 5 = Symptoms are incapacitating – unable to do activities
(1) Velanovich – Diseases of the Esophagus (2007) 20, 130-134
72. Sustained Control of GERD Symptoms
Mean Total GERD-HRQL Score
% of Patients ≥ 50% Reduction in GERD-HRQL
50
92% at 12 months
GERD-HRQL Score (Mean)
93% at 24 months
40
30
20
10
0
Baseline Off Baseline On 12 Month Post 24 Month Post
PPI PPI LINX Off PPI LINX Off PPI
73. Heartburn Questions: Mean Score
Incapacitating
unable to do
activities Baseline off 12 month Post LINX 24 month Post LINX
Affect daily
activities
Bothersome
every day
Noticeable, both
ersome, not
every day
Noticeable, b
ut not
bothersome
No Symptoms
How bad? Lying down?
Standing up?
After meals?
Change yourWake from sleep?
diet?
75. Elimination of Daily PPI Dependence
Free of Daily PPI Dependence
Baseline 12 Months 24 Months
Post-LINX Post-LINX
0% 91% 92%
PPI Frequency of Use
Frequency Baseline 12 Months 24 Months
Post-LINX Post-LINX
QD 64% 7% 7%
BID 35% 2% 1%
TID 1% 0% 0%
76. PPI Free Days
As of Last Follow-Up
900
800
700
Days Free of PPIs
600
500
400
300
200
100
0
82. Sustained Control of Regurgitation
Severity of Regurgitation
MODERATE: Predictable with position change
SEVERE: Constant regurgitation, presence of aspirations
100
Percent of Patients Reporting
80
60
40
20
0
Baseline 12 Month Post Linx 24 Month Post Linx
Note: As actively queried by Foregut Questionnaire
83.
84. Control of Esophagitis
LA Grade Severity
Grade A Grade B Grade C Grade D
100
Percent of Patients Reporting
80
60
40
20
0
Baseline 12 Month Post LINX 24 Month Post LINX
86. Minimal Side Effects
Ability to Belch
• 99% of patients throughout study period
Inability to Vomit
• 0% at 12 months
• 1% at 24 months
Note: As actively queried by Foregut Questionnaire
87. Reduced Gas Bloat
Severity of Gas Bloat
FREQUENTLY CONTINOUSLY
100
Percent of Patients Reporting
80
60
40
20
0
Baseline 12 Month Post LINX 24 Month Post LINX
Note: As actively queried by Foregut Questionnaire
88. High Level of Patient Satisfaction
How satisfied are you with your present condition?
24 Months
GERD-HRQL Baseline 12 Months
Post-LINX
Satisfaction Off PPI Post-LINX
Off PPI
Off PPI
Satisfied 0% 95% 90%
Neutral 5% 2% 7%
Dissatisfied 95% 3% 3%
91. Serious Adverse Events – Related or Unknown
Subject ID Event Description Status
03-005-004 Dysphagia Explanted 31 days after implant Resolved
Nausea
03-004-004 Dysphagia Explanted 93 days after implant Resolved
Odynophagia
03-008-021 Dysphagia Explanted 21 days after implant Resolved
03-008-018 Pain Hospitalized for pain; Resolved (pain)
Vomiting Explanted 357 days after implant for Ongoing, no follow-up
vomiting deemed necessary
(vomiting)
03-008-020 Vomiting Hospitalized 2 days after implant for <2 Resolved
days
03-018-002 Nausea Hospitalized 2 days after implant for <2 Resolved
days
92. LINX Device Can Be Removed
Laparoscopic procedure
No complications related to removal
Anatomy not significantly altered
Nissen fundoplication an option after removal
93. Summary of Related Adverse Events
Adverse Event1 % Subjects
Dysphagia 68%
Pain 24%
Stomach Bloating 14%
Nausea 7%
Odynophagia 8%
Hiccups 8%
Inability to belch or vomit 6%
1 AEs with Frequency >5%
94. Dysphagia Observations
Any complaint reported per protocol
Post-op diet was NOT restricted
Characterization of dysphagia
Mild and well tolerated in large majority of cases
Not a daily occurrence in >90% subjects
High levels of satisfaction (GERD-HRQL)
Effective management
Dilations are a safe and effective option
95. Dysphagia Observations
% of Subjects with Ongoing Dysphagia by Visit and
Intensity
Mild Moderate Severe
100
Percent of Patients Reporting
80
60
40
20
0
3 Month 6 Month 12 Month 24 Month
96. GERD-HRQL Difficulty Swallowing
Baseline 12-month 24-month
100
Percent of Patients Reporting
80
60
40
20
0
None
Noticeable, not bothersome
Noticeable, bothersome, not every day
Bothersome every dayIncapacitating, unable to do act
Affects daily activities
Foregut Questionnaire BL 3M 6M 12M 24M
Events/wk 1.4 2.1 1.9 1.8 1.2
98. Chest Pain – Severity and Frequency
Baseline Month 12 Month 24
Severity % (n/N) % (n/N) % (n/N)
None 31.0% (31/100) 80.0% (76/95) 84.4% (76/90)
Minimal – Occasional 36.0% (36/100) 16.8% (16/95) 11.1% (10/90)
episodes
Moderate – Predictable 21.0% (21/100) 3.2% (3/95) 4.4% (4/90)
with position change,
straining or lying down
Severe – Interfering with 12.0% (12/100) 0.0% (0/95) 0.0% (0/90)
activities of daily life
Change from BL
Month 12 Month 24
Improved 61.1% (58/95) 63.3% (57/90)
Same 34.7% (33/95) 30.0% (27/90)
Worsened 4.2% (4/95) 6.7% (6/90)
Frequency/Week Baseline Month 12 Month 24
N 99 95 90
Mean±SD (Median) 23.9±81.2 (2.0) 1.1±6.0 (0.0) 0.2±0.6 (0.0)
Range 0.0, 700.0 0.0, 56.0 0.0, 4.0
Note: As actively queried by Foregut Questionnaire
99. Overall Acceptable Safety Risk
144 patients implanted between 2-4 years
No deaths
No intra-operative complications
No device failures
No device erosions or migrations
Serious Adverse Events
6% (8/144)
No late onset (>1 year)
100. Conclusion / Observations
Device closely reproduces native LES function - dynamic
Improvement over current surgical options
Very few can perform a good fundoplication – tricky operation
Greatly ameliorates the side effects
Low complications and favorable pattern of failure
Addresses a significant unmet need
Positively transforms patients’ lives
LINX would be a tremendous positive addition to current
options for GERD
101. AGENDA
Todd Berg
Introduction CEO
Torax Medical
Tom DeMeester, MD
Pathophysiology of GERD Professor of Surgery, Chair Emeritus
Department of Surgery -- USC
Device Overview and Todd Berg
CEO
Pre-Clinical Activities Torax Medical
LINX Feasibility and Pivotal Daniel Smith, MD
Chair Department of Surgery – Mayo
IDE Clinical Trials Jacksonville
Todd Berg
Post Market Studies and CEO
Torax Medical
Closing Comments
103. Extended Follow Up -Pivotal Trial
Screen Implant 3m 6m 12m 24m 36mo 48mo 60mo Type of
follow-up
X X Health History
X X X X X X X X GERD-HRQL Questionnaire
X X X X X X X X Foregut Symptom
Questionnaire
X X X X X X X X PPI, H2, Antacid and other
Medication Use
X X Esophageal pH
X X Manometry/Motility
X X X X EGD Endoscopy
X X Barium Esophagram
(Fluoroscopy)
X X X X Abdominal/Chest X-ray
X X X X X X X X Adverse Events
104. Proposed Post Approval Study
Primary Objectives
Confirm long-term safety and efficacy benefits
Design
Prospective, multi-center, single-arm study
25 sites and 200 patients
Endpoints
Serious device related adverse events
Maintain control of symptoms (≥ 50% reduction in the
total GERD-HRQL score)
106. The Successful LINX Patient
Post-LINX
Baseline
% of Pts
% of Pts Characteristic
2 Years
100% Daily PPI dependence 8%
70% Reflux affecting their sleep on a daily basis 2%
76% Reflux affecting their food tolerances on a daily 2%
basis
57% Moderate or severe regurgitation including 1%
aspirations
55% Severe heartburn affecting their daily life 1%
51% Experiencing extra esophageal symptoms in addition 12%
to heartburn and/or regurgitation
40% Esophagitis 11%